Measuring Glioma Treatment Success
- Dr. Jay-Jiguang Zhu at UTHealth Houston Neurosciences says glioma treatment success is measured by three key factors: overall survival, progression-free survival, and quality of life, emphasizing that no single metric tells the full story.
- Molecular testing, now a standard part of glioma care, helps doctors understand a tumor’s genetic characteristics and tailor treatment, since each patient’s tumor behaves differently.
- Quality of life remains a critical treatment goal, with doctors focusing on maintaining independence, cognitive function, emotional well-being, and the ability to continue daily activities such as work and self-care.
Dr. Zhu is a neuro-oncologist, a neurologist who specializes in brain tumors at UTHealth Houston Neurosciences.
Read MoreEvery Tumor Is Different
“Everybody is different, and also, the tumor is different,” Dr. Zhu says. “The pathology is different. The molecular characteristics are different as well.”Today, doctors classify brain tumors not only by how the cells look under a microscope but also by their genetic features.
Molecular testing (testing that looks for specific changes in a tumor’s genes) is considered the standard of care (something all patients need and should get) when diagnosing and treating gliomas. Gliomas can either have a normal IDH gene (known as IDH wild-type) or carry a change, or mutation, in that gene. IDH mutations are more common in slower-growing gliomas.
Molecular testing is typically performed on a sample of tumor tissue. This tissue is obtained from either surgery or a biopsy. Pathologists conduct the testing; these doctors are specially trained to study tumor tissue characteristics.
Measure 1: Overall Survival
The first measure is overall survival: how long people live after diagnosis or after starting treatment. Researchers usually report it as a median, the point at which half of the people in a study had lived longer, and half had not.
For glioblastoma, the most aggressive glioma, the landmark trial that set today’s standard treatment found a median survival of 14.6 months with radiation plus the chemotherapy pill temozolomide (Temodar), compared with 12.1 months with radiation alone, according to research published in 2005 in the New England Journal of Medicine.
Many people live longer, and your doctor can tell you what applies to your tumor type.
Measure 2: Progression-Free Survival
The second measure is how long the tumor stays under control.
“We call that progression-free survival,” Dr. Zhu says. The tumor has “progressed” when it grows or causes new problems. Your doctor makes that call using MRI scans and how you feel and function.
Scans can be tricky to read. In the first 12 weeks after radiation, changes on MRI can look like tumor growth when they are actually treatment effects. Experts recommend confirming suspected progression with a repeat scan or a tissue sample during that window.
When the First Two Measures Move Together, and When They Don’t
Dr. Zhu explains that progression-free survival and overall survival often track together. Research supports that in general. A 2014 analysis published in the medical journal Neuro-Oncology found a strong link between the two in 91 glioblastoma trials.
However, they do not always line up.
In 2014, the New England Journal of Medicine published data on a large trial of the drug bevacizumab (Avastin) for newly diagnosed glioblastoma; the tumor stayed in check longer (10.7 vs. 7.3 months), yet people did not live longer (15.7 vs. 16.1 months). People on bevacizumab also had more decline in memory and thinking over time. For this reason, Dr. Zhu’s third measure matters.
Measure 3: Quality of Life
“Then the third is quality of life,” Dr. Zhu adds.
He says a big part of his “quality of life” measurement is independence. Being able to take care of yourself “with minimal help from caregivers or family members.” Doctors call these everyday tasks activities of daily living (ADLs), such as eating, dressing, bathing, and getting in and out of bed.
Work is part of quality of life for many people.
“We still have patients with glioblastoma who are working,” Dr. Zhu says. “If you continue to work, that’s wonderful.”
Your Mind and Mood Matter Too
Dr. Zhu also talks about the mind.
“You could be in a positive territory, or you could be the other way in what we call depression,” he says, “and that obviously would adversely affect our quality of life.”
Depression is common and treatable. Feeling low is never a personal failure. Tell your care team, because help is available.
“The doctors, the family, and the patient work together to fight against the disease,” Dr. Zhu says. At his center, neurologists, neurosurgeons, neuro-oncologists, and radiation oncologists review each patient’s case together.
Questions to Ask Your Care Team
- What are the molecular features of my tumor, and how do they affect my outlook?
- How will we decide whether a change on my MRI is the tumor or a treatment effect?
- How might this treatment affect my energy, thinking, and daily activities?
- Can I keep working, and what support is available if I want to?
- Who can I talk to if I feel anxious or depressed?
Learn more about SurvivorNet's rigorous medical review process.
